{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,23]],"date-time":"2026-05-23T09:09:46Z","timestamp":1779527386228,"version":"3.53.1"},"reference-count":55,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2026,3,28]],"date-time":"2026-03-28T00:00:00Z","timestamp":1774656000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,3,28]],"date-time":"2026-03-28T00:00:00Z","timestamp":1774656000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100005564","name":"Gilead Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005564","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Rheumatol Ther"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1007\/s40744-026-00828-3","type":"journal-article","created":{"date-parts":[[2026,3,28]],"date-time":"2026-03-28T08:11:29Z","timestamp":1774685489000},"page":"491-543","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Efficacy\/Effectiveness, Safety and Treatment Persistence of Filgotinib in Rheumatoid Arthritis: A Narrative Review of Clinical Trials and Real-World Evidence"],"prefix":"10.1007","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0807-7139","authenticated-orcid":false,"given":"Yoshiya","family":"Tanaka","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter C.","family":"Taylor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey A. S.","family":"Ritsema","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akira","family":"Kondo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshihiko","family":"Kaise","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,28]]},"reference":[{"issue":"1","key":"828_CR1","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1186\/s40364-025-00760-8","volume":"13","author":"Y Ma","year":"2025","unstructured":"Ma Y, Chen H, Lv W, Wei S, Zou Y, Li R, et al. Global, regional and national burden of rheumatoid arthritis from 1990 to 2021, with projections of incidence to 2050: a systematic and comprehensive analysis of the Global Burden of Disease study 2021. Biomark Res. 2025;13(1):47.","journal-title":"Biomark Res"},{"key":"828_CR2","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1547763","volume":"16","author":"L Wei","year":"2025","unstructured":"Wei L, Chen X, Liu M. Global, regional, and national burden and trends of rheumatoid arthritis among the elderly population: an analysis based on the 2021 Global Burden of Disease study. Front Immunol. 2025;16:1547763.","journal-title":"Front Immunol"},{"issue":"10391","key":"828_CR3","doi-asserted-by":"publisher","first-page":"1878","DOI":"10.1016\/S0140-6736(23)00457-9","volume":"401","author":"N Conrad","year":"2023","unstructured":"Conrad N, Misra S, Verbakel JY, Verbeke G, Molenberghs G, Taylor PN, et al. Incidence, prevalence, and co-occurrence of autoimmune disorders over time and by age, sex, and socioeconomic status: a population-based cohort study of 22 million individuals in the UK. Lancet. 2023;401(10391):1878\u201390.","journal-title":"Lancet"},{"key":"828_CR4","doi-asserted-by":"crossref","unstructured":"Radu AF, Bungau SG. Management of rheumatoid arthritis: an overview. Cells. 2021;10(11).","DOI":"10.3390\/cells10112857"},{"issue":"7","key":"828_CR5","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1002\/acr.24596","volume":"73","author":"L Fraenkel","year":"2021","unstructured":"Fraenkel L, Bathon JM, England BR, St. Clair EW, Arayssi T, Carandang K, et al. 2021 American College of Rheumatology guideline for the treatment of rheumatoid arthritis. Arthritis Care Res. 2021;73(7):924\u201339.","journal-title":"Arthritis Care Res"},{"issue":"1","key":"828_CR6","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1136\/ard-2022-223356","volume":"82","author":"JS Smolen","year":"2023","unstructured":"Smolen JS, Landew\u00e9 RBM, Bergstra SA, Kerschbaumer A, Sepriano A, Aletaha D, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update. Ann Rheum Dis. 2023;82(1):3\u201318.","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"828_CR7","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1093\/mr\/road098","volume":"34","author":"H Kameda","year":"2024","unstructured":"Kameda H, Yamaoka K, Yamanishi Y, Tada M, Koike R, Nakajima A, et al. Japan College of Rheumatology guidance for the use of methotrexate in patients with rheumatoid arthritis: secondary publication. Mod Rheumatol. 2024;34(1):1\u201310.","journal-title":"Mod Rheumatol"},{"issue":"10","key":"828_CR8","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2022-069681","volume":"13","author":"Y Li","year":"2023","unstructured":"Li Y, Lau LKW, Peng K, Zhang D, Dong D, Wong ICK, et al. Factors influencing choice of b\/ts DMARDs in managing inflammatory arthritis from a patient perspective: a systematic review of global evidence and a patient-based survey from Hong Kong. BMJ Open. 2023;13(10):e069681.","journal-title":"BMJ Open"},{"issue":"3","key":"828_CR9","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1038\/s41584-021-00726-8","volume":"18","author":"Y Tanaka","year":"2022","unstructured":"Tanaka Y, Luo Y, O\u2019Shea JJ, Nakayamada S. Janus kinase-targeting therapies in rheumatology: a mechanisms-based approach. Nat Rev Rheumatol. 2022;18(3):133\u201345.","journal-title":"Nat Rev Rheumatol"},{"key":"828_CR10","doi-asserted-by":"publisher","first-page":"2217","DOI":"10.2147\/PPA.S117774","volume":"10","author":"R Alten","year":"2016","unstructured":"Alten R, Kr\u00fcger K, Rellecke J, Schiffner-Rohe J, Behmer O, Schiffhorst G, et al. Examining patient preferences in the treatment of rheumatoid arthritis using a discrete-choice approach. Patient Prefer Adherence. 2016;10:2217\u201328.","journal-title":"Patient Prefer Adherence"},{"key":"828_CR11","unstructured":"Japan College of Rheumatology. \u5168\u4f8b\u5e02\u8ca9\u5f8c\u8abf\u67fb\u306e\u305f\u3081\u306e\u30d5\u30a3\u30eb\u30b4\u30c1\u30cb\u30d6\u9069\u6b63\u4f7f\u7528\u30ac\u30a4\u30c9. 2024."},{"issue":"6","key":"828_CR12","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1007\/s40262-022-01129-y","volume":"61","author":"F Namour","year":"2022","unstructured":"Namour F, Anderson K, Nelson C, Tasset C. Filgotinib: a clinical pharmacology review. Clin Pharmacokinet. 2022;61(6):819\u201332.","journal-title":"Clin Pharmacokinet"},{"key":"828_CR13","doi-asserted-by":"publisher","first-page":"2499","DOI":"10.2147\/PPA.S417677","volume":"17","author":"Y Tanaka","year":"2023","unstructured":"Tanaka Y, Genovese MC, Matsushima H. Long-term safety, efficacy, and patient-centered outcomes of filgotinib in the treatment of rheumatoid arthritis: current perspectives. Patient Prefer Adherence. 2023;17:2499\u2013516.","journal-title":"Patient Prefer Adherence"},{"key":"828_CR14","unstructured":"Jyseleca tablets package insert Japan. https:\/\/pins.japic.or.jp\/pdf\/newPINS\/00068995.pdf."},{"issue":"6","key":"828_CR15","doi-asserted-by":"publisher","first-page":"561","DOI":"10.7861\/clinmed.2020-0727","volume":"20","author":"PC Taylor","year":"2020","unstructured":"Taylor PC. Update on the diagnosis and management of early rheumatoid arthritis. Clin Med. 2020;20(6):561\u20134.","journal-title":"Clin Med"},{"issue":"5","key":"828_CR16","doi-asserted-by":"publisher","first-page":"1335","DOI":"10.1007\/s40744-023-00583-9","volume":"10","author":"Y Tanaka","year":"2023","unstructured":"Tanaka Y, Taylor PC, Elboudwarej E, Hertz A, Shao X, Malkov VA, et al. Filgotinib modulates inflammation-associated peripheral blood protein biomarkers in adults with active rheumatoid arthritis and prior inadequate response to methotrexate. Rheumatol Ther. 2023;10(5):1335\u201348.","journal-title":"Rheumatol Ther"},{"issue":"1","key":"828_CR17","first-page":"161","volume":"10","author":"Y Tanaka","year":"2023","unstructured":"Tanaka Y, Atsumi T, Aletaha D, Bartok B, Pechonkina A, Han L, et al. Benefit of filgotinib, a JAK1 preferential inhibitor, in rheumatoid arthritis patients with previous rapid radiographic progression: post hoc analysis of two trials. Rheumatol Ther. 2023;10(1):161\u201385.","journal-title":"Rheumatol Ther"},{"issue":"1","key":"828_CR18","first-page":"53","volume":"10","author":"BG Combe","year":"2023","unstructured":"Combe BG, Tanaka Y, Buch MH, Nash P, Burmester GR, Kivitz AJ, et al. Efficacy and safety of filgotinib in patients with high risk of poor prognosis who showed inadequate response to MTX: a post hoc analysis of the FINCH 1 study. Rheumatol Ther. 2023;10(1):53\u201370.","journal-title":"Rheumatol Ther"},{"issue":"3","key":"828_CR19","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1007\/s40744-025-00757-7","volume":"12","author":"Y Tanaka","year":"2025","unstructured":"Tanaka Y, Westhovens R, Sun H, Van der Donckt C, Zhong Y, Kaise T. Filgotinib radiographic and clinical efficacy versus other JAK inhibitors and adalimumab in patients with rheumatoid arthritis and inadequate response to methotrexate: a systematic review and network meta-analysis. Rheumatol Ther. 2025;12(3):453\u201368.","journal-title":"Rheumatol Ther"},{"issue":"4","key":"828_CR20","doi-asserted-by":"publisher","first-page":"1661","DOI":"10.1093\/rheumatology\/keae486","volume":"64","author":"MH Buch","year":"2025","unstructured":"Buch MH, Walker D, Edwards CJ, Barry J, Akroyd L, Ekoka Omoruyi EV, et al. Efficacy and safety of filgotinib in patients with moderately active rheumatoid arthritis and an inadequate response to methotrexate. Rheumatology (Oxford). 2025;64(4):1661\u201371.","journal-title":"Rheumatology (Oxford)"},{"issue":"7","key":"828_CR21","doi-asserted-by":"publisher","first-page":"848","DOI":"10.1136\/annrheumdis-2020-219214","volume":"80","author":"B Combe","year":"2021","unstructured":"Combe B, Kivitz A, Tanaka Y, van der Heijde D, Simon JA, Baraf HSB, et al. Filgotinib versus placebo or adalimumab in patients with rheumatoid arthritis and inadequate response to methotrexate: a phase III randomised clinical trial. Ann Rheum Dis. 2021;80(7):848\u201358.","journal-title":"Ann Rheum Dis"},{"key":"828_CR22","doi-asserted-by":"publisher","DOI":"10.3390\/jpm13091303","author":"M Benucci","year":"2023","unstructured":"Benucci M, Bardelli M, Cazzato M, Laurino E, Bartoli F, Damiani A, et al. ReLiFiRa (Real Life Filgotinib in Rheumatoid arthritis): retrospective study of efficacy and safety in common clinical practice. J Pers Med. 2023. https:\/\/doi.org\/10.3390\/jpm13091303.","journal-title":"J Pers Med"},{"issue":"5","key":"828_CR23","first-page":"991","volume":"42","author":"L La Barbera","year":"2024","unstructured":"La Barbera L, Rizzo C, Camarda F, Atzeni F, Miceli G, Molica Colella AB, et al. Effectiveness and safety of filgotinib in rheumatoid arthritis: a real-life multicentre experience. Clin Exp Rheumatol. 2024;42(5):991\u20138.","journal-title":"Clin Exp Rheumatol"},{"key":"828_CR24","doi-asserted-by":"crossref","unstructured":"Raimondo V, Caminiti M, Olivo D, Gigliotti P, L\u2019Andolina M, Muto P, et al. Real-life use of filgotinib in rheumatoid arthritis: a retrospective cohort study. J Clin Med. 2024;13(23):7185.","DOI":"10.3390\/jcm13237185"},{"issue":"1","key":"828_CR25","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1007\/s00393-024-01506-x","volume":"84","author":"O Schultz","year":"2025","unstructured":"Schultz O, Fiehn C, Kneitz C, Picker N, Kromer D, Zignani M, et al. Real-world experience with filgotinib for rheumatoid arthritis in Germany: a retrospective chart review. Z Rheumatol. 2025;84(1):39\u201347.","journal-title":"Z Rheumatol"},{"issue":"Supplement_3","key":"828_CR26","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keaf142.150","volume":"64","author":"MK Nisar","year":"2025","unstructured":"Nisar MK, Bhat S, Bouzid O, Daud T, Debray TPA, Galloway J, et al. P110 Baseline characteristics, disease activity, patient-reported outcomes and safety in patients with rheumatoid arthritis treated with filgotinib in the UK: up to 1-year interim results from FILOSOPHY. Rheumatology. 2025;64(Supplement_3):keaf142.50.","journal-title":"Rheumatology"},{"key":"828_CR27","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2024-004476","author":"MH Buch","year":"2024","unstructured":"Buch MH, Aletaha D, Combe BG, Tanaka Y, Caporali R, Schulze-Koops H, et al. Efficacy and safety of filgotinib in patients with rheumatoid arthritis: week 156 interim results from a long-term extension study. RMD Open. 2024. https:\/\/doi.org\/10.1136\/rmdopen-2024-004476.","journal-title":"RMD Open"},{"issue":"5","key":"828_CR28","first-page":"1043","volume":"42","author":"M Fornaro","year":"2024","unstructured":"Fornaro M, Caporali R, Biggioggero M, Bugatti S, De Stefano L, Cauli A, et al. Effectiveness and safety of filgotinib in rheumatoid arthritis patients: data from the GISEA registry. Clin Exp Rheumatol. 2024;42(5):1043\u201350.","journal-title":"Clin Exp Rheumatol"},{"key":"828_CR29","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1016\/j.ard.2025.05.960","volume":"84","author":"P Verschueren","year":"2025","unstructured":"Verschueren P, Bos R, Burmester GR, Escudero-Contreras A, Bouzid O, Debray TPA, et al. POS0578 Real-world effectiveness of filgotinib in patients with rheumatoid arthritis treated for up to 2 years in clinical practice: interim results from FILOSOPHY and PARROTFISH. Ann Rheum Dis. 2025;84:779\u201380.","journal-title":"Ann Rheum Dis"},{"issue":"Suppl 1","key":"828_CR30","doi-asserted-by":"publisher","first-page":"1565","DOI":"10.1136\/annrheumdis-2024-eular.789","volume":"83","author":"J Avouac","year":"2024","unstructured":"Avouac J, Burmester GR, Caporali RF, Debray TPA, De Leonardis F, Galloway J, et al. AB0569 patient-reported outcomes (PROs), disease activity and safety in 1177 patients with rheumatoid arthritis (RA) treated with filgotinib for up to 18 months: interim results from FILOSOPHY and PARROTFISH. Ann Rheum Dis. 2024;83(Suppl 1):1565.","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"828_CR31","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2023-003839","volume":"10","author":"PC Taylor","year":"2024","unstructured":"Taylor PC, Kavanaugh A, Nash P, Pope J, Pongratz G, Fautrel B, et al. Impact of filgotinib on pain control in the phase 3 FINCH studies. RMD Open. 2024;10(1):e003839.","journal-title":"RMD Open"},{"issue":"1","key":"828_CR32","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1186\/s13075-021-02677-7","volume":"24","author":"CO Bingham 3rd","year":"2022","unstructured":"Bingham CO 3rd, Walker D, Nash P, Lee SJ, Ye L, Hu H, et al. The impact of filgotinib on patient-reported outcomes and health-related quality of life for patients with active rheumatoid arthritis: a post hoc analysis of phase 3 studies. Arthritis Res Ther. 2022;24(1):11.","journal-title":"Arthritis Res Ther"},{"issue":"6","key":"828_CR33","doi-asserted-by":"publisher","first-page":"836","DOI":"10.1136\/annrheumdis-2011-200343","volume":"71","author":"C Bombardier","year":"2012","unstructured":"Bombardier C, Barbieri M, Parthan A, Zack DJ, Walker V, Macarios D, et al. The relationship between joint damage and functional disability in rheumatoid arthritis: a systematic review. Ann Rheum Dis. 2012;71(6):836\u201344.","journal-title":"Ann Rheum Dis"},{"key":"828_CR34","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2022-002543","author":"R Landew\u00e9","year":"2023","unstructured":"Landew\u00e9 R, Sun L, Chen YF, Daojun M, van der Heijde D. Robust analyses for radiographic progression in rheumatoid arthritis. RMD Open. 2023. https:\/\/doi.org\/10.1136\/rmdopen-2022-002543.","journal-title":"RMD Open"},{"issue":"11","key":"828_CR35","doi-asserted-by":"publisher","first-page":"656","DOI":"10.1038\/nrrheum.2012.153","volume":"8","author":"G Schett","year":"2012","unstructured":"Schett G, Gravallese E. Bone erosion in rheumatoid arthritis: mechanisms, diagnosis and treatment. Nat Rev Rheumatol. 2012;8(11):656\u201364.","journal-title":"Nat Rev Rheumatol"},{"issue":"6","key":"828_CR36","doi-asserted-by":"publisher","first-page":"1399","DOI":"10.1007\/s40744-023-00590-w","volume":"10","author":"Y Tanaka","year":"2023","unstructured":"Tanaka Y, Takeuchi T, Atsumi T, Combe BG, Aletaha D, Kaise T, et al. Prevention of radiographic progression in higher-risk patients with rheumatoid arthritis using filgotinib in phase III studies: narrative review of post hoc analyses. Rheumatol Ther. 2023;10(6):1399\u2013415.","journal-title":"Rheumatol Ther"},{"issue":"1","key":"828_CR37","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1007\/s40744-024-00725-7","volume":"12","author":"Y Tanaka","year":"2025","unstructured":"Tanaka Y, Atsumi T, Aletaha D, Schulze-Koops H, Fukada H, Watson C, et al. The uncoupling of disease activity from joint structural progression in patients with rheumatoid arthritis treated with filgotinib. Rheumatol Ther. 2025;12(1):53\u201366.","journal-title":"Rheumatol Ther"},{"issue":"Suppl 1","key":"828_CR38","doi-asserted-by":"publisher","first-page":"1448","DOI":"10.1136\/annrheumdis-2023-eular.5289","volume":"82","author":"K Katayama","year":"2023","unstructured":"Katayama K, Tanaka K, Kawahata T, Yuichi M, Okubo T, Sato T, et al. AB0507 Filgotinib may be useful therapy for rapid radiographic progression by reducing bone edema. Ann Rheum Dis. 2023;82(Suppl 1):1448.","journal-title":"Ann Rheum Dis"},{"issue":"9","key":"828_CR39","doi-asserted-by":"publisher","first-page":"1110","DOI":"10.1136\/ard-2024-225759","volume":"83","author":"GR Burmester","year":"2024","unstructured":"Burmester GR, Gottenberg JE, Caporali R, Winthrop KL, Tanaka Y, Ekoka Omoruyi EV, et al. Integrated safety analysis of filgotinib in patients with moderate-to-severe rheumatoid arthritis over a treatment duration of up to 8.3 years. Ann Rheum Dis. 2024;83(9):1110\u20137.","journal-title":"Ann Rheum Dis"},{"key":"828_CR40","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2022.769329","volume":"9","author":"IL Noronha","year":"2022","unstructured":"Noronha IL, Santa-Catharina GP, Andrade L, Coelho VA, Jacob-Filho W, Elias RM. Glomerular filtration in the aging population. Front Med (Lausanne). 2022;9:769329.","journal-title":"Front Med (Lausanne)"},{"key":"828_CR41","unstructured":"European Medicines Agency. Jyseleca 200 mg film-coated tablets - Summary of Product Characteristics (SmPC) - (emc) | 11810. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/jyseleca-epar-product-information_en.pdf."},{"issue":"5","key":"828_CR42","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1016\/j.ard.2025.01.032","volume":"84","author":"P Nash","year":"2025","unstructured":"Nash P, Kerschbaumer A, Konzett V, Aletaha D, D\u00f6rner T, Fleischmann R, et al. Expert consensus statement on the treatment of immune-mediated inflammatory diseases with Janus kinase inhibitors: 2024 update. Ann Rheum Dis. 2025;84(5):664\u201379.","journal-title":"Ann Rheum Dis"},{"key":"828_CR43","doi-asserted-by":"publisher","first-page":"784","DOI":"10.1016\/j.ard.2025.05.966","volume":"84","author":"K Bevers","year":"2025","unstructured":"Bevers K, Betteridge N, Galloway J, Gatti D, Debray TPA, Van der Donckt C, et al. POS0584\u2005Overall safety profile and laboratory parameters in patients with rheumatoid arthritis treated with filgotinib for up to 2 years: Real-world evidence from FILOSOPHY and PARROTFISH. Ann Rheum Dis. 2025;84:784\u20135.","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"828_CR44","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1177\/02537176241297953","volume":"47","author":"C Andrade","year":"2024","unstructured":"Andrade C. Poorly recognized and uncommonly acknowledged limitations of randomized controlled trials. Indian J Psychol Med. 2024;47(1):83\u20135.","journal-title":"Indian J Psychol Med"},{"issue":"4","key":"828_CR45","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1093\/mr\/roaf007","volume":"35","author":"T Takeuchi","year":"2025","unstructured":"Takeuchi T, Pfeifer C, Zhong Y, Piao Y, Kaise T, Tani M. Real-world treatment persistence in csDMARD-IR and bDMARD-IR patients with rheumatoid arthritis in Japan: a large claims database study. Mod Rheumatol. 2025;35(4):626\u201336.","journal-title":"Mod Rheumatol"},{"key":"828_CR46","unstructured":"J\u00e9r\u00f4me Avouac NB, Bevers K, Burmester G, Caporali R, Bouzid O, Debray T, Van der Donckt C, Galloway J, Romero-Yuste S and Verschueren P. Early and sustained improvements in disease activity and patient-reported outcomes in patients treated with filgotinib for rheumatoid arthritis: Up to 2-year interim real-world data from FILOSOPHY and PARROTFISH. American College of Rheumatology Convergence 2025. 2025."},{"key":"828_CR47","unstructured":"Nakayamada S, Takahashi N, Nakajima A, Nakajima A, Fujii T, Abe A, Nishida K, Zhong Y, Yates M, Aoki K, Akiko Y, Ishii M, Takatori Y, Takagi M, Kuwana M, Okamoto N, Tanaka Y. Safety of filgotinib (FIL) in patients (pts) with rheumatoid arthritis (RA): Interim results of all-case post-marketing surveillance (PMS) in Japan (third report). The 69th Annual Gerneral Assembly and Scientific Meeting of the Japan College of Rheumatology (Fukuoka, Japan). 2025."},{"issue":"1","key":"828_CR48","doi-asserted-by":"publisher","DOI":"10.1007\/s10238-024-01360-w","volume":"24","author":"Y Nakayama","year":"2024","unstructured":"Nakayama Y, Onishi A, Yamamoto W, Yoshikawa A, Shiba H, Yoshida N, et al. Safety of Janus kinase inhibitors compared to biological DMARDs in patients with rheumatoid arthritis and renal impairment: the ANSWER cohort study. Clin Exp Med. 2024;24(1):97.","journal-title":"Clin Exp Med"},{"issue":"2","key":"828_CR49","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1136\/ard-2024-226156","volume":"84","author":"S Fukui","year":"2025","unstructured":"Fukui S, Winkelmayer WC, Tedeschi SK, Marrugo J, Guan H, Harrold L, et al. Disease activity of rheumatoid arthritis and kidney function decline: a large prospective registry study. Ann Rheum Dis. 2025;84(2):201\u20139.","journal-title":"Ann Rheum Dis"},{"issue":"57 Suppl 7","key":"828_CR50","doi-asserted-by":"publisher","first-page":"vii54","DOI":"10.1093\/rheumatology\/key109","volume":"57","author":"S Monti","year":"2018","unstructured":"Monti S, Grosso V, Todoerti M, Caporali R. Randomized controlled trials and real-world data: differences and similarities to untangle literature data. Rheumatology (Oxford). 2018;57(57 Suppl 7):vii54\u20138.","journal-title":"Rheumatology (Oxford)"},{"key":"828_CR51","unstructured":"ClinicalTrials.gov. Prospective Observational Study of Filgotinib in Subjects With Rheumatoid Arthritis (FILOSOPHY) NCT04871919 https:\/\/clinicaltrials.gov\/study\/NCT04871919."},{"key":"828_CR52","unstructured":"Eisai. Zyseleka Tablet 100\u00a0mg, 200\u00a0mg. https:\/\/www.eisaikorea.com\/board\/product\/board_view.php?search_division=IMMUNE&search_category=2&num=1010."},{"key":"828_CR53","unstructured":"Health Science Authority (HSA). Jyseleca Prescribing Information."},{"key":"828_CR54","unstructured":"Taiwan Food and Drug Administration. Jyseleca 100 mg Prescribing Information https:\/\/urlisolation.com\/browser?clickId=05DFDABD-7FDA-4F80-B8B6-FA0F8F390C12&traceToken=1753344342%3Bgilead_hosted%3Bhttps%3A%2Flmspiq.fda.gov.tw%2Fweb%2FDRP&url=https%3A%2F%2Flmspiq.fda.gov.tw%2Fweb%2FDRPIQ%2FDRPIQ1000Result%3FlicBaseId%3D5ED983D4-053A-4C5F-8922-F7BBF4257B58."},{"key":"828_CR55","unstructured":"Taiwan Food and Drug Administration. Jyseleca 200 mg Prescribing Information https:\/\/urlisolation.com\/browser?clickId=71D10896-68F8-4DBC-BE49-D65A1DFB93EB&traceToken=1753344849%3Bgilead_hosted%3Bhttps%3A%2Flmspiq.fda.gov.tw%2Fweb%2FDRP&url=https%3A%2F%2Flmspiq.fda.gov.tw%2Fweb%2FDRPIQ%2FDRPIQ1000Result%3FlicBaseId%3D4A0D5BFC-C1EB-4C05-A2C6-2DEA7C393229."}],"container-title":["Rheumatology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40744-026-00828-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40744-026-00828-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40744-026-00828-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,23]],"date-time":"2026-05-23T08:46:48Z","timestamp":1779526008000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40744-026-00828-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,28]]},"references-count":55,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["828"],"URL":"https:\/\/doi.org\/10.1007\/s40744-026-00828-3","relation":{},"ISSN":["2198-6576","2198-6584"],"issn-type":[{"value":"2198-6576","type":"print"},{"value":"2198-6584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,28]]},"assertion":[{"value":"17 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Yoshiya Tanaka has received speaking fees and\/or honoraria from Chugai, UCB, Abbvie, AstraZeneca, Eli Lilly & Co, Behringer-Ingelheim, GlaxoSmithKline, Eisai, IQVIA, Daiichi-Sankyo, Otsuka, Taisho, Gilead, Bristol-Mayers. Yoshiya Tanaka is an Editorial Board member of\n                      Rheumatology and Therapy\n                      . Yoshiya Tanaka was not involved in the selection of peer reviewers for the manuscript nor any of the subsequent editorial decisions. Peter C Taylor has received research grants from Alfasigma, consulting fees from AbbVie, Aceleryn, Alfasigma, Gilead, Takeda, Janssen, Eli Lilly & Co., Nordic Pharma, Roche, and UCB, and has served on safety monitoring boards for Immunovant, Moonlake and Sanofi. Jeffrey A S Ritsema is an employee of Alfasigma Nederland BV. Toshihiko Kaise is an employee of Gilead Sciences K.K. and shareholder of Gilead Sciences, Inc. Akira Kondo is an employee of Gilead Sciences K.K. and may hold shares in Gilead Sciences, Inc.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"As this review is based on previously conducted studies and does not contain any new studies with human participants or animals performed by any of the authors, ethical approval is not required.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}